ZINC GLUCONATE TRIHYDRATE

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C6H11O7.Zn.3H2O
Molecular Weight	509.75
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.O.[Zn++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O

InChI

InChIKey=ZPQPBMFYUZNVPE-BMDZSJGYSA-L

InChI=1S/2C6H12O7.3H2O.Zn/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;;;;/h2*2-5,7-11H,1H2,(H,12,13);3*1H2;/q;;;;;+2/p-2/t2*2-,3-,4+,5-;;;;/m11..../s1

HIDE SMILES / InChI

Molecular Formula	Zn
Molecular Weight	65.409
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C6H12O7
Molecular Weight	196.1553
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459
Curator's Comment: description was created based on several sources, including http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity

Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Streptococcus mutans 41 Target ID: CHEMBL612426 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 \| https://www.ncbi.nlm.nih.gov/pubmed/2913640	Inhibitor 8297
respiratory burst 39 Target ID: GO:0045730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8157083	Activator 1430
transformed cell apoptotic process 108 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Activator 1430
Methotrexate 38 Target ID: CHEMBL2364710 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Hydrolytic Enzyme 38
ultraviolet B-induced damage 38 Target ID: ultraviolet B-induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/25947194	Interacts 323
T cell mediated immunity 40 Target ID: GO:0002456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Activator 1430
Zinc transporter ZIP1 38 Target ID: Q9NY26 Gene ID: 27173.0 Gene Symbol: SLC39A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 1064
Zinc transporter ZIP2 38 Target ID: Q9NP94 Gene ID: 29986.0 Gene Symbol: SLC39A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 1064

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Unknown 2578
Unknown 2578
Caries 43 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 https://www.ncbi.nlm.nih.gov/pubmed/2913640 https://www.ncbi.nlm.nih.gov/pubmed/6353570	Preventing	Basic research	Unknown Approved Use Unknown
Ulcerative colitis 123 Sources: https://www.drugs.com/international/corticotropin-zinc-hydroxide.html https://www.ncbi.nlm.nih.gov/pubmed/13469787	Primary	Approved 8429	CORTROPHIN-ZINC Approved Use Treatment of ulcerative colitis and other colonic disorders. Launch Date 1955
Zinc deficiency 39 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6383773	Primary	Preclinical	Unknown Approved Use Unknown
Acute myeloid leukemia 136 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Primary	Basic research	Unknown Approved Use Unknown
Breast cancer 434 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27305766	Primary	Basic research	Unknown Approved Use Unknown
Renal insufficiency 40 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Secondary	Approved 8429	VORAXAZE Approved Use Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate. Launch Date 2012
Diaper dermatitis 38 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021026s000lbl.pdf	Primary	Approved 8429	VUSION Approved Use INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. Launch Date 2006
Poison Ivy dermatitis 38 Sources: https://www.drugs.com/cdi/zinc-oxide-cream.html	Primary	Approved 8429	ZINC OXIDE Approved Use Unknown
Gastrointestinal disorders 95 Sources: https://www.drugs.com/pro/zinc-sulfate-injection.html	Primary	Approved 8429	ZINC SULFATE Approved Use Unknown Launch Date 1987
Mucositis 39 Sources: https://clinicaltrials.gov/ct2/show/NCT01015183	Primary	Phase III 656	ZINC SULFATE Approved Use Unknown Launch Date 1987
Dysgeusia 38 Sources: https://clinicaltrials.gov/ct2/show/NCT00036881	Primary	Phase III 656	ZINC SULFATE Approved Use Unknown Launch Date 1987
Unknown 2578

PubMed

Title	Date	PubMed
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.	1991 Apr 1	9996367
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1.	1991 Sep 10	1888732
Iron chelators as therapeutic agents against Pneumocystis carinii.	1994 May	8067783
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.	1995 Nov 13	7488149
Thujaplicin-copper chelates inhibit replication of human influenza viruses.	1998 Aug	9806486
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.	2000 Sep	10978858
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.	2002 Mar 1	11877378
Thermotoga maritima-Escherichia coli chimeric topoisomerases. Answers about involvement of the carboxyl-terminal domain in DNA topoisomerase I-mediated catalysis.	2004 Jul 16	15140883
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.	2004 Jul 16	15131129
Impact of the mother's zinc deficiency on the woman's and newborn's health status.	2005	16240669
Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2.	2005 Apr 27	15857667
[Reduced thymulin production during occupational exposure to lead].	2005 Jan-Mar	15915658
Copper and zinc concentrations in serum of healthy Greek adults.	2006 Apr 15	15955548
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.	2006 Dec	17093223
Effect of end-stage renal disease and diabetes on zinc and copper status.	2006 Jul	16943612
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.	2006 May	16636303
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.	2007 May	17301066
DNA damaging potential of zinc oxide nanoparticles in human epidermal cells.	2009 Mar 28	19382294
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.	2010 Feb	19755143
Glucarpidase following high-dose methotrexate: update on development.	2010 Jan	19925307
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.	2010 Jan 12	19897006
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.	2010 Jul	20194077
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.	2011 Mar 21	21341804
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.	2011 Sep	21642632
Molecular cloning, characterization of copper/zinc superoxide dismutase and expression analysis of stress-responsive genes from Eisenia fetida against dietary zinc oxide.	2012 Mar	22137962
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.	2013 Dec	24060544
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.	2013 Jan	22083529
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.	2013 Jul 31	23726862
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.	2013 Mar	23232460
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.	2013 Nov 25	24120544
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.	2013 Sep	23352990
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.	2014 Jan	23832296
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.	2014 Mar 3	24374571
Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.	2014 May 15	24780487
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.	2014 May 16	24614525
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.	2016 Mar 5	26561748
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process.	2016 Oct	27248459
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.	2016 Oct 1	27546855
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.	2016 Sep	26892107
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.	2016 Sep 21	27530867

Patents

Sample Use Guides

In Vivo Use Guide

Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.

Route of Administration: Oral

In Vitro Use Guide

Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:26:44 GMT 2023` Edited by `admin` on `Fri Dec 15 16:26:44 GMT 2023`
Record UNII	F2F0XU34WQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZINC GLUCONATE TRIHYDRATE

Common Name

English

ZINC, BIS(D-GLUCONATO-O1,O2)-, TRIHYDRATE, (T-4)

Common Name

English

ZINC, BIS(D-GLUCONATO-.KAPPA.O1,.KAPPA.O2)-, TRIHYDRATE, (T-4)-

Common Name

English

ZINC GLUCONATE 3H2O

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID00154138